Zdrowie i gospodarka · 23/08/1994

Sandoz Pharmaceuticals Corp.; Bromocriptine Mesylate (Parlodel) for the Prevention of Physiological Lactation; Opportunity for a Hearing on a Proposal To Withdraw Approval of the Indication

The Food and Drug Administration (FDA) is proposing to withdraw approval of Parlodel (bromocriptine mesylate) for preventing physiological lactation due to a reevaluation finding the drug not safe for use under its approved conditions.